Several studies have shown that imp

Several studies have shown that impairments in QoL and functioning often persist beyond the clinical resolution of depressive symptoms,4 placing patients at an increased risk of relapse and leading to higher direct and indirect costs.5 Notably, the severity of depressive symptoms has been found to explain only partially the impairment of QoL.3,4,6–8 This suggests that assessing depressive symptoms alone may not be sufficient to measure the success of MDD interventions.7 There is thus a growing interest in complementing traditional symptom measures with additional QoL measures when evaluating treatment effectiveness.8,9Selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) are two classes of antidepressants with a better